Rezolute is trading at $4.89 (+5.38%) on October 9, amid biotech-sector strength; no direct cause of the move was confirmed. - XBI was reported up 2.50% during the regular session, supporting a sector-based context. - No new company announcement specific to October 9 was identified. - The FDA’s October 5 recommendation to request a pre-BLA meeting and subsequent analyst optimism are recent background, not a confirmed cause of today’s move.